Nabilone for the Treatment of Dementia-Associated Sexual Disinhibition

Zajac, Daria M.; Sikkema, Sarah R.; Chandrasena, Ranjith

doi:10.4088/pcc.14l01695

Cited by 10 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, five studies were controlled trials [17][18][19][20][21] , three were openlabel/observational studies, and seven were case reports. 16,[22][23][24][25][26][27][28][29][30] To facilitate description of the findings, the publications selected were grouped in the following subsections, according to the neuropsychiatric domains targeted by the intervention: (a) agitation; (b) sleep disturbances; (c) abnormal sexual behavior.…”

Section: Resultsmentioning

confidence: 99%

“…16,26 Notably, in patients with severe FTD, nabilone was effective for control of agitation and aggression, 26 with reduced disinhibition and sexual disorders. 27 Favorable results were also observed in patients with FTD suffering from agitation and anxiety who were given CBD (medical marijuana). 30 Conversely, in two controlled trials (level of evidence 1), enrolling patients with severe AD, VD, and AD/ VD, who were suffering from agitation and other NPS, the authors found no significant differences between dronabinol and placebo.…”

Section: Efficacymentioning

confidence: 99%

See 1 more Smart Citation

Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review

Stella¹,

Valiengo²,

Paula³

et al. 2021

Trends Psychiatry Psychother

View full text Add to dashboard Cite

Introduction: Neuropsychiatric symptoms are an integral component of the natural history of dementia, occurring from prodromal to advanced stages of the disease process and causing increased burden and morbidity. Clinical presentations are pleomorphic and clinical management often requires combinations of pharmacological and non-pharmacological interventions. However, limited efficacy and a non-negligible incidence of adverse psychotropic drug events emphasize the need for novel therapeutic options. Objectives: To review the evidence supporting use of medical cannabinoids for treatment of neuropsychiatric symptoms (NPS) of dementia. Methods: We conducted a systematic review of the medical literature to examine scientific publications reporting use of medical cannabinoids for treatment of NPS. Medical Subject Headings (MeSH) were used to search for relevant publications and only papers reporting original clinical information were included. A secondary search was performed within selected publications to capture relevant citations that were not retrieved by the systematic review. The papers selected were categorized according to the level of evidence generated by the studies in relation to this clinical application, i.e. (1) controlled clinical trials;(2) open-label or observational studies; and (3) case reports. Results: Fifteen publications with original clinical data were retrieved: five controlled clinical trials, three open-label/observational studies, and seven case reports. Most studies indicated that use of medical cannabinoids engendered favorable outcomes for treatment of NPS related to moderate and advanced stages of dementia, particularly agitation, aggressive behavior, sleep disorder, and sexual disinhibition. Conclusion: Medical cannabinoids constitute a promising pharmacological approach to treatment of NPS with preliminary evidence of benefit in at least moderate to severe dementia. Controlled trials with longitudinal designs and larger samples are required to examine the long-term efficacy of these drugs in different types and stages of dementia, in addition to their adverse events and risk of interactions with other drugs. Many pharmacological details are yet to be determined, such as dosing, treatment duration, and concentrations of active compounds (e.g., cannabidiol [CBD]/ Δ 9 -tetrahydrocannabinol [THC] ratio) in commercial preparations of medical cannabinoids.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Efficacymentioning

confidence: 99%

Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review

Stella¹,

Valiengo²,

Paula³

et al. 2021

Trends Psychiatry Psychother

View full text Add to dashboard Cite

show abstract

“…97 With this mechanism in mind, cannabinoid receptor agonists, such as THC, have been investigated to treat BPSD. 98,99 Various cannabinoids have been explored for the treatment of BPSD, including dronabinol, [100][101][102][103] nabilone, [104][105][106][107] pure THC, 16,53,[108][109][110] and THC/CBD. 111 A 2019 systematic review identified six randomized, controlled trials (RCTs), two cohort studies, and four case series that evaluated safety and effectiveness of cannabinoids in treating BPSD.…”

Section: Fda-approved Uses Of Cannabismentioning

confidence: 99%

“…Various cannabinoids have been explored for the treatment of BPSD, including dronabinol, 100–103 nabilone, 104–107 pure THC, 16,53,108–110 and THC/CBD 111 . A 2019 systematic review identified six randomized, controlled trials (RCTs), two cohort studies, and four case series that evaluated safety and effectiveness of cannabinoids in treating BPSD 112 .…”

Section: Pharmaceutical Uses and Proposed Medicinal Purposes Of Canna...mentioning

confidence: 99%

Cannabis Use in Older Adults: A Perspective

Solomon

Greenstein

DeLisi

2021

Harv Rev Psychiatry

View full text Add to dashboard Cite

The prevalence of cannabis use among older adults (aged 65 and above) for both recreational and medicinal purposes has significantly increased in recent years. Information regarding the safety of cannabis in this population is important since aging is associated with metabolic changes, multiple morbidities, increases in prescription medication use, and an overall decline in functioning. In this Perspectives article, we review special considerations pertinent to older adults—specifically, the impact of cannabis on cognition and on falls and injuries, its drug interactions, and its potential medicinal applications for treating the behavioral and psychological symptoms of dementia. Knowledge about the role of cannabis in brain health, injury risk, and drug interactions remains limited since the available evidence stems primarily from adolescent and young adult cohorts, plus a limited number of small observational studies with older adults. In terms of utilizing certain cannabinoids to treat the behavioral and psychological symptoms of dementia, some studies have found promising results, but because of the lack of consistency in the literature, it is premature to draw conclusions. Controlled research trials specifically with geriatric participants are needed to understand the effects of cannabis use in this vulnerable population.

show abstract

“…On the other hand, the synthetic CB counterparts are frequently classified for its study. Such classification led in 2002 to a group of 4 components that remains valid nowadays: classic CBs (HU-210, 64 nabilone, 65,66 cannabidiol, 67,68 and other); nonclassic CBs (CP-47,497, 69,70 CP-55,244, 71 and CP-55,940 69 ), aminoalkylindoles (R-(+)-WIN 55,212-2, 72 and JWH-015 73 ), and eicosanoids (AEA 74 as the most notable as well as methanandamide 75 and arachidonoyl-2-chloroethylamide 76 ) to name a few, that account as synthetic eicosanoids. 77…”

Section: The Endocannabinoid System: Overviewmentioning

confidence: 99%

Potential Therapeutic Targets of the Endocannabinoid System in Common Neurodegenerative Disorders and Organic Acidemias

Aguilera

Santamarı́a

2017

Journal of Inborn Errors of Metabolism and Screening

View full text Add to dashboard Cite

The cannabinoid chemistry is currently being addressed in preclinical approaches as a viable therapeutic alternative for the management of a wide range of signs, symptoms, and some biochemical hallmarks of many neurological pathologies (such as neuroinflammation and neurodegeneration). This clinical orientation is grounded on the consistent promissory profile that cannabinoid compounds have shown, and the great necessity of feasible options to undergo such disorders. Even though at early research stages, metabolic disorders are starting to rise as potential targets of cannabinoid alternatives; approaches in this term could, in turn, aim to modulate the endocannabinoid response for therapeutic purposes. This review recalls the pathologic scenarios endured in the course of neurological diseases of high occurrence and the most typical metabolic disorders, while discussing the neuroprotective mechanisms of cannabinoid agonists in the central nervous system, and the potential targets of the endocannabinoid system and metabolic disorders.

show abstract

Nabilone for the Treatment of Dementia-Associated Sexual Disinhibition

Cited by 10 publications

References 15 publications

Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review

Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review

Cannabis Use in Older Adults: A Perspective

Potential Therapeutic Targets of the Endocannabinoid System in Common Neurodegenerative Disorders and Organic Acidemias

Contact Info

Product

Resources

About